18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer - Trial NCT06414902
Access comprehensive clinical trial information for NCT06414902 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 1
Nov 29, 2024
Oct 01, 2027
Primary Outcome
Safety and adverse events (AEs)
Summary
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and
 predict a participant's response to treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06414902
Non-Device Trial